What is Pattern Bioscience?
Pattern Bioscience is at the forefront of diagnostic innovation, developing technology that delivers results in hours, a critical advancement for reducing unnecessary antibiotic prescriptions in hospitals. Their solutions target healthcare providers across all common infection sites, addressing the urgent global crisis of antibiotic misuse and aiming to improve patient outcomes. The company's commitment to faster, smarter diagnostic tools positions it as a key player in the healthcare technology sector.
How much funding has Pattern Bioscience raised?
Pattern Bioscience has raised a total of $137.7M across 5 funding rounds:
Series A
$6.4M
Series B
$15.4M
Series C
$28.7M
Private Equity
$44.2M
Series D
$43M
Series A (2019): $6.4M, investors not publicly disclosed
Series B (2020): $15.4M led by Omnimed Capital and Illumina Ventures
Series C (2023): $28.7M supported by Illumina Ventures, Antimicrobial Resistance Action Fund, Omnimed Capital, and Daleshaw
Private Equity (2025): $44.2M, investors not publicly disclosed
Series D (2025): $43M backed by Illumina Ventures and The AMR Action Fund
Key Investors in Pattern Bioscience
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health. The company supports various portfolio companies that are advancing life science research, biopharmaceutical drug development, and gene editing technologies.
The AMR Action Fund
The AMR Action Fund is dedicated to overcoming technical and funding barriers in antibiotic development, aiming to ensure a sustainable pipeline of new antibiotics to combat superbugs. They invest in biotechnology companies that are creating treatments for patients with life-threatening antimicrobial-resistant infections.
Omnimed Capital
Omnimed Capital is an investment firm that likely focuses on healthcare and life sciences, providing capital to companies advancing medical technologies and solutions. Their participation suggests a strategic interest in the diagnostics and antimicrobial resistance space.
What's next for Pattern Bioscience?
The recent major enterprise-level funding and strategic investment signal a new phase of growth and scaling for Pattern Bioscience. This capital infusion is expected to accelerate the company's market penetration, further development of its ID/AST platform, and expansion of its reach within the healthcare ecosystem. The backing from prominent investors focused on life sciences and antimicrobial resistance suggests a strategic alignment with global health priorities, positioning Pattern Bioscience for significant impact in the fight against superbugs.
See full Pattern Bioscience company page
